| abstract |
The present invention provides an androgen receptor targeting agent (ARTA). The medicament defines a new subclass of compounds that is a selective androgen receptor modulator (SARM). Some SARM compounds have been found to have unexpected androgen and assimilation activity of nonsteroidal ligands on androgen receptors. Other SARM compounds have been found to have unexpected antiandrogen activity of nonsteroidal ligands on androgen receptors. The SARM compound, alone or as a composition, may comprise a) male contraception; b) various hormone-related symptoms such as tiredness, depression, reduced libido, sexual disorders, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteoporosis, prostatic hyperplasia, Treatment of symptoms associated with androgen reduction (ADAM) in older men, such as emotional and cognitive changes, and prostate cancer; c) women, such as sexual disorders, reduced libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, cognitive and emotional changes, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer Treatment of symptoms associated with androgen reduction (ADIF) in women; d) treatment and / or prevention of acute and / or chronic myotropia; e) prevention and / or treatment of dry eyes; f) oral androgen replacement therapy; g) reducing the incidence, arrest or decline of prostate cancer; And / or h) induce apoptosis in cancer cells.n n n n Selective androgen receptor modulator, halogenation, androgen receptor, osteoporosis, prostate cancer, hormone therapy |